Freeline Announces Proposed ADS Ratio Change
LONDON, April 21, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq:FRLN) today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value £0.00001 per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to fifteen (15) ordinary shares (the “ADS Ratio Change”). The company anticipates that the ADS Ratio Change will be effective on or about May 12, 2023 (the “Effective Date”).
Related news for (FRLN)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLN
- Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update
- Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
- Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)